AVEO Pharmaceuticals (AVEO) In A Perilous Reversal

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Trade-Ideas LLC identified AVEO Pharmaceuticals ( AVEO) as a "perilous reversal" (up big yesterday but down big today) candidate. In addition to specific proprietary factors, Trade-Ideas identified AVEO Pharmaceuticals as such a stock due to the following factors:

  • AVEO has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $41.5 million.
  • AVEO has traded 106,498 shares today.
  • AVEO is down 3.6% today.
  • AVEO was up 7.3% yesterday.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in AVEO with the Ticky from Trade-Ideas. See the FREE profile for AVEO NOW at Trade-Ideas

More details on AVEO:

AVEO Pharmaceuticals, Inc., a biopharmaceutical company, develops targeted therapies for patients with cancer and related diseases. Currently there are no analysts that rate AVEO Pharmaceuticals a buy, no analysts rate it a sell, and 2 rate it a hold.

The average volume for AVEO Pharmaceuticals has been 3.5 million shares per day over the past 30 days. AVEO has a market cap of $130.5 million and is part of the health care sector and drugs industry. The stock has a beta of 1.76 and a short float of 0.2% with 0.01 days to cover. Shares are up 176.1% year-to-date as of the close of trading on Wednesday.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you liked this article you might like

How I've Prepared for Hurricane Irma -- and a Market Pullback

How I'm Prepared for Irma -- and a Pullback

AVEO Pharmaceuticals (AVEO) Stock Pops on European Licensing Agreement

When Eyeing Small Biotechs, Partnerships Are Huge

When Eyeing Small Biotechs, Partnerships Are Huge

Exelixis Scores Much-Needed Kidney Cancer Study Win to Boost Drug Sales